Cambridge Healthtech Institute's Fourth Annual

Characterization of Biotherapeutics

( 生物学疗法的特性评估 )

Improving Prediction, Screening and Characterization of New Biologic

2018年1月8日 - 9日

 

New biotherapeutics formats are flooding the discovery and development pipelines and with this comes an increasing need for better and faster characterization tools and strategies, improved biomolecular and biophysical assays for the new biotherapeutics. The Fourth Annual Characterization of Biotherapeutics conference will present new tools, strategies and case studies on analytical development and characterization of mAbs, ADCs, bispecifics, and other novel protein formats, biosimilars, HOS, and developability. We are looking for cutting edge tools, research findings and unpublished data to be featured at this forum.

We invite you to present a poster and attend to join with colleagues in this discussion of the key challenges and solutions improving predication, screening and characterization of new biologics.

Preliminary Agenda


CHARACTERIZATION OF NEW BIOTHERAPEUTICS

Novel Low-Protein Consuming High Throughput Biophysical Methods for mAbs, ADCs and Multi-Specific Biologics Characterization

Alexey Rak, Ph.D., Head of Bio Structure and Biophysics, Integrated Drug Discovery, Sanofi R&D

Engineering Biparatopic Anti-HER2 Antibody: Function Follows Form

Vaheh Oganesyan, M.S., Scientist, MedImmune


HIGHER ORDER STRUCTURE AND BIOPHYSICAL CHARACTERIZATION

Critical Considerations in the Characterization of Protein Higher Order Structure (HOS) and Its Relationship with Stability and Function

Haripada Maity, Ph.D., Research Advisor, Formulation Development, CMC Development, Eli Lilly and Company

Higher Order Structure (HOS) Characterization in Biologics and Structure, Function and Stability Relationship

Jared Bee, Ph.D., Analytical Development Group Leader, MacroGenics, Inc.


HIGH THROUGHPUT SCREENING, IMMUNOASSAY AND BIOCHEMICAL ASSAY

In Vitro Assays to Predict Immunogenicity Risk Assessment of Protein Therapeutics

Shanmuuga T. Sundaram, Ph.D., Research Advisor, BioAnalytical Sciences, Bioproduct Research and Development, Eli Lilly and Company

Deciphering the Root-Causes for Atypical PK of mAbs and Complex Biologics by Protein Engineering

Thomas Kraft, Ph.D., Postdoctoral Scientist, Large Molecule Research, Roche Diagnostics GmbH


DEVELOPABILITY ASSESSMENT AND ANALYTICAL CHARACTERIZATION

Developability Assessment of Therapeutic Proteins - A Toolbox for Characterization of Different Formats

Thorsten Lorenz, Ph.D., Group Head Developability Assessment, Integrated Biologics Profiling, Novartis Pharma AG

Light-Induced Buffer Component Adduction on Protein

Ming Lei, Ph.D., Senior Research Associate, Protein Analytical Chemistry, Genentech


BIOSIMILARS AND ANALYTICAL COMPARABILITY

Performing Biosimilarity - An Industry Perspective on Recent Projects

Urs Lohrig, Ph.D., Lab Head, Phys-Chem-Characterisation Biosimilars, Biologics Technical Development & Manufacturing, Sandoz GmbH


* 活动内容有可能不事先告知作更动及调整。